Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A...

NDAQ:BOLT - Post by User

Bolt Biotherapeutics Inc

<< Previous

Bullboard Posts

Next >>

(11)
•••

Post by TradeVanguard27on Nov 27, 2024 3:54pm

69 Views

Post# 36334339

BOLT Completes NI 43-101 Report for Switchback Property—Reso

Bolt Metals has wrapped up its NI 43-101 technical report for the Switchback Copper-Silver Property. This milestone could pave the way for resource estimates and future development. Investors, watch for upcoming drill results!

<< Previous

Bullboard Posts

Next >>

Mink Ventures defines eight new high-priority drill targets